SVA dividend history

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed at the Company's website at www.sinovac.com.cn or www.sinovac.com and at the SEC's website www.sec.gov. The Company also announced its unaudited and unreviewed financial results for the second half of 2025 and audited financial results for the full year ended December 31, 2025. Second Half and Full Year of 2025 Financial Summary Sales for

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company's previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company's common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has no

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2025. First Half of 2025 Financial Summary Sales for the six months ended June 30, 2025 were $130.3 million, compared to $128.7 million in the prior year period. The Company posted $21.7 million of net loss attributable to common shareholders, or a loss of $0.30 per basic and diluted share, in the six months ended June 30, 2025, compared to net income attributable to common shareholders of $93.9 million, or an income of $1.31 per basic and diluted share, in the prior year period.

In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at sva@dfking.com The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

On July 7 Antigua Court restricted PIPE shares from voting in Special Shareholder Meeting, but Eastern Caribbean Court of Appeal granted a temporary stay of the injunction shortly before Special Meeting 2018 PIPE transaction authorized by the former board deemed an "Imposter Board" by UK Privy Council Board continues to govern Company and remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders Paying Agent has begun distributing the special cash dividend of US$55.00 per common share to SINOVAC shareholders The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider

Court Found That 1Globe and Li Likely Violated Disclosure Obligations; Mandates Both File Updated Disclosures Within 5 Days of Order Decision Cites Prolonged Pattern of Corruption and Deception by 1Globe and Li Vivo Calls on All Shareholders to Support SAIF's Slate of Qualified Nominees, Reject 1Globe's Deception, and Stand Up for Transparent Corporate Governance Ahead of Special Meeting of Shareholders on July 8, 2025 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today announced that the United States District Court of Ma

Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card "FOR" its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ("SAIF Partners", "we" or "us"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company") which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote "FOR" the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the "Boar

Glass Lewis concludes, "[T]he current board has demonstrated credible progress in restoring governance stability and operational normalcy. [...] The Dissident Group's proposals, by contrast, rest on an inconsistent platform, rely on individuals linked to the governance failures of the past, and raise material questions about their ability to credibly resolve the challenges ahead." SINOVAC's Current Board of Directors encourages shareholders to follow Glass Lewis' Recommendation and VOTE the WHITE proxy card "AGAINST" the misguided proposals to remove the SINOVAC Board and appoint the Reconstituted Imposter Former Board Slate Special Meeting of SINOVAC shareholders to be held on July 8,

Highlights Current Board's Empty Promises, Failure to Deliver Value for Shareholders, and Certain Directors' Concerning Patterns of Reckless, Unethical and Illegal Actions to Retain Control of Sinovac SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card "FOR" its Director Nominees to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ("SAIF Partners"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company"), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board's empty promises to shareholders, nume

Reaffirms Commitment to Declaring Dividends and New Dividend Policy Underscores Pledge to Work with NASDAQ Toward Resuming Trading Continues to Diligently Defend Against the Dissenting Investor Group's Multi-Jurisdictional Legal Tactics to Block the US$55.00 Per Common Share Cash Dividend The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today sent a letter to shareholders ahead of the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). The full text of the letter follows:

SAIF Partners Nominees Will Work Proactively to Help Shareholders Realize Full Value of Sinovac, Including Through the Payment of Significant Dividends and Resumption of Trading of Common Shares Current Board – With Most Directors Not Duly Elected By Shareholders and Not Sanctioned By Privy Council – Never Prioritized Taking Action to Resume Trading or Pay Dividends, Until Pressured By Shareholders Sinovac Management – and Not the Current Board – is Working Actively to Make Funds Available for a US$55 Per Share Dividend Distribution Urges Sinovac Shareholders to VOTE the GOLD Proxy Card FOR the Election of SAIF's Director Nominees, and Discard the Company's White Card SAIF Partners

Highlights bold steps to restore fairness to SINOVAC's common shareholders and deliver long-term value creation Urges shareholders to VOTE the WHITE proxy card "AGAINST" the misguided proposals to remove SINOVAC's Board and appoint the Reconstituted Imposter Former Board Slate Launches dedicated website: www.VoteSinovac.com The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) as a Form 6-K and launched a website, www.VoteSinovac.com, with important information and resources in connec

Corrects the Record Following Latest Attempt By the 1Globe Activist Board to Distort Reality in Transparent Attempt to Mislead Shareholders Notes That on Friday Antiguan Judge Denied the 1Globe Activist Board's Attempt to Immediately Prevent Prime Success From Voting Sinovac Shares – Which the Board Failed to Disclose to Shareholders Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued a statement in response to the decision by the United States District Court for the Southern District of

New York Court Denies Advantech/Prime's Petition for Emergency Injunctive Relief Clears Legal Hurdle for Dividend Paying Agent to Payout the Special Cash Dividend of US$55.00 Per Common Share on July 7, 2025 SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ("Advantech/Prime") Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the "Dissenting Inves

Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote "AGAINST" the misguided proposals to remove SINOVAC's Board and appoint the Reconstituted Imposter Former Board Slate The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with t

Accelerates payment of previously announced special cash dividend of US$55.00 per common share Decides to declare second special cash dividend of US$19.00 per common share Intends to declare third special cash dividend between US$20.00 – US$50.00 per common share Adopts new dividend policy to regularly return cash to shareholders The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company's governance framework. Currently, a dissenting investor group led by Advantech/Prime Succes

Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued a statement in response to the Company's continued false, misleading and outright fabricated claims relating to the upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for July 8, 2025. Prime Success stated: "We believe shareholders deserve the truth – which is why we feel compelled to yet again correct the record, this time regarding the "alert" released on June 16 by the Board currently controlling Sinovac (the "

Vivo Capital Challenges SINOVAC's Paying Agent on Distribution of the Dividend Opposition Brief to be Filed Monday in Advance of Wednesday Hearing and Expected Friday Decision The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on

For More Information, Visit www.SaveSinovac.com Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued the following letter in response to the Company's recent false and misleading claims relating to the upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for July 8, 2025. The full text of the letter is below and available at www.SaveSinovac.com. Dear fellow Sinovac shareholders, Prime Success, L.P. (together with its affiliates, "Prime Success" or "we"), a signifi

Intends to file definitive proxy materials in the coming days Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025 are entitled to vote at the meeting. SINOVAC's Board of Directors (the "SINOVAC Board") also issued a letter to shareholders.

Details Why Change is Needed on Sinovac's Board in Order to Restore Company's Previous Success and Reverse Value-Destructive Path Taken Under Current Board Affirms Commitment to Seeing Company Reinstate Trading on the NASDAQ, Fairly Issue Dividends and Overhaul Corporate Governance Encourages Shareholders to Support Slate of Director Nominees Proposed by SAIF for Election at Upcoming July 8 Special Meeting For More Information, Visit www.SaveSinovac.com Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC's common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enter

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the "Board") issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the "Vivo group") against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo group's recent press releases, lawsuits and other actions against SINOVAC and the Board, particularly those related to the Board's decision to declare a cash dividend of US$55.00 per common share to SINOVAC shareholders. The Vi

Beijing, April 22, 2025 (GLOBE NEWSWIRE) -- To the Shareholders of Sinovac Biotech Ltd. and Other Stakeholders: The management of Sinovac Biotech Ltd. (NASDAQ:SVA, "SINOVAC" or the "Company")) recently received notice of its external auditor's decision to resign from its engagement for the Company's year-end audit for the fiscal year 2024. According to the resignation letter, the auditor's decision was prompted by an announcement the Company's current Board made on April 1, 2025, stating that "the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office."  The auditor expressed concern that such a

BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed.  Heng Ren previously sent the Board a letter on March 19, and received no response.  The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than suffi

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Company's board of directors (the "Board") has decided to declare a special cash dividend of US$55.00 per common share (the "Dividend"). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company to Sinovac Biotech (Hong Kong) Limited. The Dividend is intended to provide SINOVAC shareholders with their appropriate share of these prior distributions from the Company's subsidiaries. Going

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4 billion, compared to $510.6 million in the prior year. The Company posted $3.4 billion of net income attributable to common sharehol

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common shareholders, or $51.42 per basic and $44.80 per diluted share, in the six months ended June 30, 2021, compared to net loss attributable to common shareholders of $12.6 million, or $0.13 loss per basic and diluted share, in the prior year period. Mr. Weidon

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. Operating income for the fourth quarter increased by 583.7% from the prior

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial Summary Sales for the third quarter of 2020 were $115.5 million, an increase of 79.4% from $64.3 million in the prior year period. Sales for the nine months ended September 30, 2020, were $183.2 million, an increase of 11.1% from $164.9 million in the prior year period. Operating income for the third quarter of 2020 increased by 101.7% from the prior year period due to higher sales.